Clinical trials: Bacteraemia Caused by Gram-Negative Bacteria
Gram Negative Pneumonia, Gram-Negative Bacterial Infections
Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MV
This study is designed to evaluate the clinical and antibacterial efficacy, safety and pharmacokinetics of the drug Fluorothiazinone compared to placebo to prevent nosocomial gram-negative bacterial infections with participation…
- Conditions
- Gram Negative Pneumonia, Gram-Negative Bacterial Infections, Bacteremia Caused by Gram-Negative Bacteria
- Trial name
- NCT06135350
- Testing
- Fluorothiazinone, tablets 300 mg at a dose of 2400 mg/day
- Where
- 2 sites in Russia
- Volunteers
- 234 people
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Bacteremia, Healthcare-associated Pneumonia
Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria
Background and rationale: Antimicrobial resistance is a global public health threat. An increasing number of Gram-negative bacteria isolates worldwide are resistant to virtually all antibiotics including carbapenems.
- Conditions
- Bacteremia, Healthcare-associated Pneumonia, Ventilator-associated Pneumonia
- Trial name
- XDR-GNB (NCT02134106)
- Testing
- Polymyxin B, Polymyxin B + Doripenem
- Where
- 2 sites in Singapore
- Sponsor
- Tan Tock Seng Hospital
Bacteremia Caused by Gram-Negative Bacteria, Bacterial Pneumonia
A Post-Marketing Study to Assess the Efficacy and Safety of Intravenous Polymyxin B and Colistin Methanesulfonate in Patients With Carbapenem-Resistant Gram-Negative Bacterial Infection
This is a retrospective, observational, post-marketing study to evaluate the clinical response, microbiological response, mortality, and safety of intravenous polymyxin B and colistin methanesulfonate in patients with…
- Trial name
- NCT06966284
- Where
- Taiwan
- Volunteers
- 480 people
- Sponsor
- TTY Biopharm
Bloodstream Infection, Gram Negative Infections
Antibiotic Duration and Outcomes in High-Risk Febrile Neutropenia Patients
The goal of this clinical trial is to learn if a personalized duration of antibiotic therapy, based on clinical stability, is as effective as a standard duration of at least 10 days in hospitalized patients with hematologic…
- Conditions
- Bloodstream Infection, Gram Negative Infections, Bacteraemia Caused by Gram-Negative Bacteria, Febrile Neutropenia (FN)
- Trial name
- PERaSTrA (NCT07372131)
- Testing
- Clinical Stability-Driven Antibiotic Discontinuation Strategy, Standard of Care Antibiotic Duration
- Where
- Italy
- Volunteers
- 172 people
- Sponsor
- Valeria Cento
Sepsis, Gram-Positive Bacteremia
CRP and PCT as Predictors of Sepsis Cause
The aim of this retrospective study is to determine the predictive role of serum level of procalcitonin (PCT) and c-reactive protein (CRP) in determining the causative agent of sepsis in surgical intensive care unit (ICU)…
- Conditions
- Sepsis, Gram-Positive Bacteremia, Gram-negative Bacteremia
- Trial name
- NCT05605275
- Testing
- PCT levels, CRP levels, White blood cell count
- Where
- Croatia
- Volunteers
- 81 people
- Sponsor
- Osijek University Hospital
Bacteraemia Caused by Gram-Negative Bacteria
Antibiotic Durations for Gram-negative Bacteremia
Gram-negative bacteremia (GNB) is a frequent hospital \& community-acquired infection, yet there is as yet no evidence from randomized studies on the optimal duration of antibiotic therapy.
- Trial name
- PIRATE (NCT03101072)
- Testing
- "Fixed long" antibiotic course of 14 days, "Fixed short" antibiotic course of 7 days, "Individualized duration" of antibiotic therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 504 people
- Sponsor
- University of Geneva, Switzerland
Bacteremia Caused by Gram-Negative Bacteria
Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection
The purpose of this study is to determine whether ceftolozane-tazobactam is as effective as meropenem with respect to 30 day mortality in the treatment of bloodstream infection due to third-generation cephalosporin…
- Trial name
- MERINO III (NCT04238390)
- Testing
- Ceftolozane-Tazobactam, Meropenem
- Where
- 29 sites in Australia, Italy and 3 more
- Sponsor
- The University of Queensland